DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

Feng Xu; Lulu He; Xueqin Zhan; Jiexin Chen; Huan Xu; Xiaoling Huang; Yangyi Li; Xiaohe Zheng; Ling Lin; Yongsong Chen

doi:doi:10.18632/aging.104129

← Back

Research Paper Volume 12, Issue 24 pp 25275—25293

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

Figure 3. Kaplan–Meier analysis of overall survival for patients with LUAD. Patients were classified according to age (age < 60 and age ≥ 60 years), sex (male and female), TNM stage (Stage I + Stage II and Stage III + Stage IV), and T stage (T1 + T2 and T3 + T4). LUAD, lung adenocarcinoma; TNM, tumor/node/metastasis.